Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glycomimetics Inc
(NQ:
GLYC
)
0.1763
+0.0031 (+1.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Glycomimetics Inc
< Previous
1
2
3
Next >
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting
December 12, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
November 09, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Two Upcoming Investor Conferences
November 08, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting
November 03, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022
November 02, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 09, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer
September 06, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022
August 03, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022
July 27, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference
June 02, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022
April 28, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report First Quarter Financial Results on April 28, 2022
April 25, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022
February 25, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 23, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer
February 23, 2022
From
GlycoMimetics, Inc.
Via
Business Wire
Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectin
December 13, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule
December 06, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML
November 23, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs
November 22, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)
November 15, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
November 11, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences
November 09, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021
November 02, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Third Quarter Financial Results on November 2, 2021
October 26, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
Efficacy and Safety Data for GlycoMimetics’ Lead Investigational Drug Uproleselan Published in BLOOD
September 23, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference
September 08, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
August 09, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021
August 05, 2021
From
GlycoMimetics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.